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Background: Acupuncture has become a viable option for migraine prophylaxis in Europe; 
however, despite its wide use, more data on the short- and long-term cost-effectiveness are needed 
when considering the perspectives of a paying third-party, the patient, and of society in general. 
The aim was to evaluate the cost and effectiveness of adjuvant acupuncture to pharmacologic 
treatment vs pharmacologic treatment alone in migraine patients after a 3-month acupuncture 
course and a 6-month follow-up from all perspectives.
Methods: The study involved an open-label randomized clinical trial of patients receiving acu-
puncture (n=42), and a waiting list control group (n=44). The number of migraine days during 
the last 28 days, as well as direct and indirect costs were considered. The trial was registered 
under DRKS00009803.
Results: The total cost per patient reached €696 vs €285 after 3 months of acupuncture and €66 vs 
€132 in the acupuncture and control groups after a 6-month follow-up, respectively (P=0.071). 
The trends observed in effectiveness and costs from all perspectives are discussed.
Conclusion: The inclusion of acupuncture in health care results beneficial mainly for its 
observed trend in reduced losses of productivity and income, with the latter often exceeding 
the costs of acupuncture treatment. As such, acupuncture may be recommended as an adjuvant 
treatment in migraine prophylaxis to standard pharmacotherapy.
Keywords: acupuncture, cost, effectiveness, migraine, prophylaxis, Traditional Chinese 
Medicine
Introduction
Migraine is classified within a group of highly prevalent brain disorders with a 
calculated cost of €662 per migraineur and representing the highest proportion of 
indirect health care costs, accounting for 87% of overall costs in comparison with 
other conditions.1,2 In Europe, one-third of the population presents at least one brain 
disorder, including migraine, resulting in an overall cost of 798 billion euro per year 
(2010).2 Migraine-associated disability often results in reduced social activities and 
work capacity, for example, in the UK some 25 million working/school-days are lost 
every year because of migraine alone.3 Still, headaches might often be overlooked, 
by both the lay public and some health care professionals, as a minor complaint and 
its impacts on physical, emotional, social health, as well as economic development, 
may not always be fully acknowledged. Further, brain disorders in general are identi-
fied as a major health economic challenge in Europe, calling for wider attention on 
behalf of the health authorities and national governments, as well as more funding 
for brain research.2
A previous meta-analysis proved that acupuncture could become a viable pro-
phylactic treatment option for frequent or uncontrolled migraine, or for migraineurs 
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experiencing drug side effects.4,5 Acupuncture is seemingly 
superior to pharmacologic treatments in terms of the occur-
rence of fewer side effects and potential long-term effective-
ness after its discontinuation.6–8 There is also some evidence 
suggesting that the introduction of acupuncture to an existing 
pharmacologic treatment can result in a reduced economic 
impact due to decreased use of medications, number of sick-
ness absence, and medical review appointments.9 Despite the 
evidence for the potential cost-effectiveness of acupuncture 
in chronic pain management, such as headache, osteoar-
thritis, and lower back pain, additional data on the long-
term cost-effectiveness of acupuncture are needed.8–11 Our 
comparative study is the first economic analysis comparing 
acupuncture with a standard pharmacologic treatment in the 
Czech Republic. The aim of the study was to evaluate the 
effectiveness and cost of acupuncture treatment in patients 
with migraine after a 3-month course of acupuncture and 
6-month follow-up from three perspectives: a third-party 
payer, the patient, and society.
Methods
experimental design
The current study is based on an open-label randomized 
clinical trial (October 2015 to April 2017), taking place at 
the Czech-Chinese Centre for Traditional Chinese Medicine 
in the University Hospital Hradec Kralove. The patients were 
randomly assigned to either acupuncture (AG) or a waiting 
list control group (CG). During a 12-week therapeutic period, 
acupuncture treatment was administered 14 times using the 
semi-standardized therapeutic acupuncture protocol. Patients 
in both groups were administered with the standard pharma-
cologic treatment (prophylactic medication and analgesics as 
needed) following the appropriate guidelines.12 The design 
of the trial including flow diagram and intervention has been 
described in detail elsewhere.13
Patients
Patients aged between 18 and 70 years, attending the 
Neurology Outpatient Clinic at the University Hospital 
Hradec Kralove, and with a clinical history of migraine of 
at least 12 months and a minimum of 4 days of migraine 
in 4 weeks, were enrolled in the study. All patients were 
diagnosed with migraine by board-certified neurologists 
according to the criteria set by the International Classifica-
tion of Headache Disorders.14 A written informed consent 
was obtained from all patients. The study was approved by 
the Ethical Committee of the University Hospital Hradec 
Kralove, registered under the code DRKS00009803.
Outcomes
The primary outcome was to compare the cost of acupuncture 
in patients with migraine after a 3-month course of treatment 
(T12) and a 6-month follow-up (T36) from three perspec-
tives: a paying third party, the patient, and society in general.
effectiveness
The effectiveness of the treatment was evaluated according 
to a previous study13, and the first parameter evaluated the 
number of migraine days in the last 4 weeks before random-
ization (baseline period) (T0), and at 12 (T12) and 36 (T36) 
weeks after randomization. A second parameter evaluated 
the reduction in relief medication use, migraine intensity and 
duration, and the number of patients with reduced migraine 
frequency ($50%) over a 4-week period. Specific quality 
of life using the Migraine Disability Assessment (MIDAS) 
was also recorded.15
costs
The present study employs the methodology established by 
Drummond,16 dividing the costs into direct and indirect cat-
egories. The former includes variable and fixed costs, whereas 
the latter includes the costs incurred by the patients and their 
families. In this regard, the psychological costs are also of a 
similar nature and therefore not negligible; however, these are 
not the subject of this paper as neither are the costs associated 
with hospitalization. Loss of productivity was calculated on 
the basis of “Human Capital Approach”.17 Direct and indirect 
costs were not discounted as the intervention period was less 
than 1 year. Prices of individual items are shown in Table 1.
In the discussion section a further division of costs is used, 
namely from a third party payer’s, a patient’s, and societal 
perspectives.18,19 The individual items under examination 
using the categories of direct and indirect costs16,20 were set as 
Table 1 Unit cost
Type of costs €a
Treatment
acupuncture (cost out-of-pocket)
Acupuncture package (an initial visit, five 
acupuncture sessions, and a check-up visit)
166.0
acupuncture follow-up session 16.6
Medication, package (reimbursement/co-payment)b –c
health care service, unit 0.04
Productivity/income loss, working day 24.52
Travels, km 0.14
Notes: a1 eUr = 27.05 cZK. bPrescription and over-the-counter drugs were 
reimbursed based on the czech National Drug Price list of 2015/201623 and priced 
at the average price calculated from the actual retail prices obtained from a sample 
of retail and hospital pharmacies in the study location in 2015/2016. cThe unit cost 
depends on the type of medication and so an average price cannot be established.
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follows: direct medical costs (medications, outpatient visits, 
acupuncture visits, emergency visits, adverse drug reactions), 
nonmedical direct costs (travel costs), and indirect costs (loss 
of income, productivity lost) (Table 2). Within the framework 
of the second parameter for costs examination, the individual 
groups are a third-party payer (outpatient visits, medication 
reimbursement, acupuncture visits, emergency visits, and 
adverse drug reactions), the patient’s perspective (medica-
tion – drugs’ surcharge, over-the-counter (OTC) drugs, travel 
costs, loss of income, acupuncture visits), and the societal 
perspective (productivity lost).
The health care costs were calculated by multiplying the 
number of units for intervention by the unit’s price. The costs 
of drugs were calculated on a consumption basis expressed as 
defined daily doses (DDDs) and the price per DDD.21 Travel 
expenses by the patients were calculated as the product of the 
number of visits to the physician and the price of each visit. 
Loss of income was recorded as a result of deterioration of 
symptoms and days off owing to an appointment with the 
physician.
resource use
The information concerning demographics data of the 
patient’s clinical condition, comorbidities, medications, 
physician’s time, and costs of health care services (visits 
to physicians, visits to emergency department [ED], hospital-
ization) were obtained from electronic patient record system 
at the Faculty Hospital in Hradec Králové.
The number of units for intervention and their unit cost 
were based on current legislation of the Czech Republic for 
2015/2016.22 Drug reimbursements were determined accord-
ing to the Numerical Index 2015/2016.23 However, there is 
no available source of information concerning the selling 
price of drugs in the Czech Republic; therefore, the selling 
price of drugs and OTC drugs were expressed as a mean 
obtained from a sample of selected hospital and community 
pharmacies in a given locality (2015/2016). The following 
data were collected from patients in the form of question-
naires: use of OTC drugs, visits to ED, hospitalization, sick 
leave, days off from work or school, and time spent at the 
physician’s office, including transit. Travel expenses were 
calculated based on the distance between the physician’s 
office and the patient’s place of residence and the price of 
fuel per kilometer.24 Productivity lost was expressed by the 
number of days off per employee, evaluating each day by 
the proportional mean gross pay for the year 2015/2016 in 
the Czech Republic and the number of working days in a year 
according to data available by the Czech Statistical Office 
in the Czech Republic.25 The costs were expressed in euros 
using purchasing power parity for the 2015/2016 year.26
statistical analysis
The statistical analyses of individual costs were performed 
using the R Project for Statistical Computing v3.3.3, and MS 
Excel 2016 was used for data manipulation. A P-value #0.05 
was considered significant in all cases and the number of 
iterations was of 1,000 in the bootstrap method. At first, 
normality was tested in 42 patients with acupuncture and in 
44 patients in the CG for individual item costs. Normality 
was tested using the Shapiro–Wilk normality test (namely, 
the function “shapiro.test” was used). Normality was rejected 
in all cases (P,0.05), and, consequently, to take account of 
the skewed distributions of the costs, the bootstrap method 
(namely, the package “boot” version 2017.2 and the function 
“boot” were used) was used with 95% CIs of the means.27 
The null hypothesis, meaning equal in the AG and the CG, 
was tested against the alternative hypothesis stating that the 
costs are lower in the AG using the bootstrap method. Conse-
quently, the resulting P-values were one tailed, and the pack-
age “boot” version 2017.2 was used in the calculations.
The cost of an acupuncture session was varied from €11 
to €35 for each patient, and all other costs were consistent 
in the analysis.
Results
sample characteristics
A total of 91 patients were enrolled in the study, and the flow 
diagram was reported elsewhere.13 There were no significant 
Table 2 Direct and indirect costs
Direct costs Indirect costs
Medical Nonmedical
Medication Travel costs loss of income
Outpatient visits Productivity loss
acupuncture visits
emergency visits
adverse drug reactions
Paying third party Patient’s 
perspective
Society’s 
perspective
Outpatient visits
Medication reimbursement
acupuncture visits
emergency visits
adverse drug reactions
Medication (drug 
surcharge, over-the-
counter drugs)
Productivity loss
Travel costs
loss of income
acupuncture visits
Note: costs dividing data from Drummond et al16 and Maresova et al.20
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differences between groups when concerning the baseline 
characteristics (Table 3).
A significant reduction in the number of migraine days 
per 4 weeks was reached at the end of the intervention 
(∆ -2.0; 95% CI: -4 to -1) as well as at the 6-month follow 
up (∆ -4.0; 95% CI: -6 to -2). A significant percentage of 
responders to treatment was noted in the AG vs CG at the 
end of the intervention (50% vs 27%; P,0.05) as well as at 
the 6-month follow-up (81% vs 36%; P,0.001). The AG 
showed a notable reduction in the intake of symptomatic 
medication compared with the CG at the end of acupuncture 
(∆ -2.7; 95% CI: -5.2 to -0.7) and the 6-month follow-up 
(∆ -3.0; 95% CI: -5.8 to -0.7). Disease-specific quality-of-
life score was improved in both groups at both time points, 
yet a reduction in the MIDAS scores remained significant 
only in the AG at the 6-month follow-up. Nevertheless, there 
was a significant difference between the number of patients 
with mild (grades I and II; mean score 0–10) vs moderate 
and severe disability (grades III and VI; mean score .10) 
before and after the intervention, as well as in the follow-up, 
in favor of the AG.13
Use of health care services
The average number of visits to the physician’s office 
remained similar in both groups at both time points (Table 4); 
on average, patients in the AG visited their acupuncturist 
13.5 times (SD 0.7). The number of migraine-related visits 
to the ED was significantly lower in the AG during acu-
puncture treatment when compared to the CG, although no 
between-group differences were found (T0: 0.4 vs T12: 0.1; 
P=0.012) (Table 4). Also, patients in the AG experienced 
fewer drug side effects compared to the CG over the course 
of acupuncture treatment; yet, the reduction did not last till 
the 6-month follow-up (Table 4). No serious adverse effects 
were reported following acupuncture treatment.
costs
The overall mean cost per patient from all the three perspec-
tives is given in Table 5. Neither of the evaluation periods for 
AG and CG showed a significant difference in the cost com-
ponents; nevertheless, the absolute amounts of changes in 
some costs are still interesting. The direct costs were always 
lower in the AG vs CG; however, at 3 months, AG costs 
were higher than those of CG (€506.4 vs €64.4) – when the 
costs associated with acupuncture visits and traveling were 
included. When these costs were not considered, however, 
the direct costs were lower in the AG.
At a 6-month follow-up, the direct and indirect total costs 
were lower in the AG, where direct costs were lower by €20 
and the indirect costs by €46.
It is worth mentioning that the costs changed over time 
for each group. Within the AG, there was a gradual decrease 
in the loss of income (T0: €6, T12: €14.0, T36: €3.7) and 
productivity loss (T0: €128.3, T12: €123.3, T36: €10.2). 
Overall, a decrease in indirect costs could be observed in 
AG, from €134.3 at the baseline to €13.9 at the 6-month 
follow-up. Direct costs within the AG were inevitably higher 
during the intervention period and then dropped (T0: €38.1, 
T12: €506.4, T36: €51.7). Within the AG direct costs show a 
gradual increment in all time periods (T0: €39.4, T12: €64.4, 
T36: €71.9); further, the absolute comparison of AG and CG 
at the 6-month follow-up period shows that the direct costs 
are higher by €20.2 in the AG.
Paying third-party perspective
From a third-party payer’s perspective, there were no sig-
nificant changes between both groups. However, there were 
lower costs for medication reimbursement in AG during 
the acupuncture treatment period (€25.6 per person) and at 
the 6-month follow-up (€29.3). Outpatient and emergency 
Table 3 Baseline patient characteristics
Characteristics Acupuncture 
group
Control 
group
N=42 N=44
age (years)
Mean (sD) 45.6 (12.8) 46.5 (10.3)
Median 47 47.5
Female, n (%) 37 (88) 39 (89)
Positive family history of migraine, n (%) 24 (57) 29 (66)
Duration of migraine (years)
Mean (sD) 26.9 (12.9) 23.0 (14.1)
Median 27.5 20.0
comorbidity, n (%) 23 (54.8) 23 (52.3)
smokers, n (%) 9 (21) 5 (11)
Migraine days
Frequency (no. per month) 11.97 (6.6) 12.1 (9.2)
Duration (hours) 12.2 (15.3) 10 (11.4)
intensity, Vas (mm) 5.2 (1.3) 5.4 (1.8)
Drug consumption (aTc/DDD)
rescue medication, mean (sD) 14.8 (14.3) 11.5 (11.8)
Prophylactic medication, mean (sD) 9.6 (11.9) 7.2 (11.9)
Migraine attack (no per month) 6.4 (2.4) 6.0 (2.7)
Migraine disability assessment score 48.9 (38.1) 52.9 (31.9)
employees (during working hours),  
n (%)
17 (40.5) 23 (52.3)
employees (unpaid hours), n (%) 3 (7.1) 5 (11.4)
Place of residency (local patients),  
n (%)
9 (21.4) 16 (36.4)
employees (during working hours),  
n (%)
17 (40.5) 23 (52.3)
Abbreviations: ATC/DDD, anatomical therapeutic classification/defined daily 
dose; Vas, visual analog scale.
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Table 4 Mean use of resources during a 3-month acupuncture treatment and a 6-month follow-up
Acupuncture group N=42 Control group N=44 P-value
Baseline year N Mean SD N Mean SD
rescue/prophylactic medication (aTc/DDD)a 42 14.8/9.6 (14.3/11.9) 44 11.5/7.2 (11.8/11.9) Ns
Outpatient visits, n 42 1.0 0.7 44 1.0 0.8 Ns
Productivity loss, working days 42 0.1 0.1 44 0.1 0.2 Ns
loss of income, unpaid working days 42 0.0 0.1 44 0.0 0.1 Ns
emergency visits 42 0.4 0.5 42 0.3 0.6 Ns
hospitalization 40 0.0 0.0 41 0.0 0.0 Ns
adverse drug reactions, n (%) 41 9 (22.0) 41 10 (24.4) Ns
Acupuncture treatment (3 months)
rescue medication (aTc/DDD)a 42 26.1 41.4 42 26.8 27.5 Ns
acupuncture visits, n 42 13.5 0.7
Productivity loss, working days 42 0.8 1.4
loss of income, unpaid working days 42 0.3 0.9
Outpatient visits, n 42 1.0 1.0 42 1.0 0.9 Ns
Productivity loss, working days 42 0.1 0.2 42 0.1 0.1 Ns
loss of income, unpaid working days 42 0.0 0.1 42 0.0 0.1 Ns
emergency visits 42 0.1* 0.4 42 0.2 0.5 Ns
hospitalization 42 0.0 0.0 42 0.0 0.0 Ns
adverse drug reactions, n (%) 42 2 (4.8) 40 6 (15.0) Ns
6-month follow-up
rescue medication (aTc/DDD)a 40 26.6 50.8 41 28.4 31.9 Ns
Outpatient visits, n 40 0.7 0.7 41 1.0 1.1 Ns
Productivity loss, working days 40 0.0* 0.1 41 0.1 0.2 Ns
loss of income, unpaid working days 40 0.0 0.0 41 0.0 0.1 Ns
emergency visits 40 0.3 0.6 39 0.4 0.7 Ns
hospitalization 40 0.0 0.0 37 0.0 0.0 Ns
adverse drug reactions, n (%) 39 7 (17.9) 38 8 (21.1) Ns
Notes: aRescue medication (ATC: N02, M01, R06). *Level of significance 0.05 (between-group comparison, unpaired t-test, Mann–Whitney test, Fisher’s exact test). level of 
significance 0.05 (within-group comparison, paired t-test, Wilcoxon signed-rank test).
Abbreviations: ATC/DDD, anatomical therapeutic classification/defined daily dose; NS, nonsignificant. 
Table 5 comparison of mean baseline and overall costs after a 3-month acupuncture treatment and a 6-month follow-up
Acupuncture group 
(N=42), cost per patient
Control group (N=44), 
cost per patient
Bootstrap t 
P-value 
(one tailed)
N Mean 95% CI N Mean 95% CI P-value Meancontrol - 
Meanacup
Baseline year
Direct costs
Medication reimbursement 42 8.6 (2.8, 14.4) 44 16.4 (0.4, 32.4) 0.89 7.8
Medication co-payment 42 9.8 (3.8, 16) 44 5.5 (2.2, 8.8) 0.89 -4.3
Outpatient visits 42 5.0 (4, 6) 44 4.6 (3.7, 5.6) 0.71 -0.4
emergency visits 42 6.4 (3.5, 9.2) 44 5.7 (2.6, 8.6) 0.64 -0.7
adverse drug reactions 42 0.6 (-0.5, 1.8) 44 0.2 (-0.1, 0.6) 0.74 -0.3
Travel costs 42 7.5 (4.3, 10.9) 44 6.8 (3.6, 9.9) 0.62 -0.7
Direct total costs 42 38.1 (-27.8, 65.2) 44 39.4 (19.8, 58.7) 0.45 1.2
Indirect costs
Productivity loss 42 128.3 (57.2, 199.9) 44 249.2 (68, 430.7) 0.24 120.9
loss of income 42 6.0 (-2.8, 15.5) 44 4.1 (-2.1, 10.3) 0.65 -1.9
(Continued)
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Table 5 (Continued)
Acupuncture group 
(N=42), cost per patient
Control group (N=44), 
cost per patient
Bootstrap t 
P-value 
(one tailed)
N Mean 95% CI N Mean 95% CI P-value Meancontrol - 
Meanacup
Indirect total costs 42 134.3 (61.1, 208.7) 44 253.4 (70.9, 439.9) 0.27 119.0
Total costs 42 172.5 (100.4, 282.2) 44 292.8 (110.8, 474.4) 0.26 120.3
Acupuncture treatment (3 months)
Direct costs
Medication reimbursement 42 15.8 (5.4, 27) 44 41.5 (-2.0, 84.3) 0.12 25.6
Medication co-payment 42 21.8 (5.9, 37.7) 44 11.1 (4.7, 17.8) 0.89 -10.7
acupuncture visits, patients 42 308.5 (304.8, 312.1)
acupuncture visits, third-party payer 42 25.1 (25.1, 25.1)
Travel acupuncture costs 42 120.8 (84.9, 155.5)
Outpatient visits 42 4.0 (2.6, 5.2) 44 4.1 (3.1, 5.1) 0.45 0.1
Travel costs 42 7.8 (4, 11.8) 44 3.7 (2.2, 5.2) 0.97 -4.1
emergency visits 42 1.8 (0, 3.9) 44 2.9 (1.1, 4.8) 0.20 1.1
adverse drug reactions 42 0.4 (-0.4, 1.2) 44 0.9 (-0.1, 1.9) 0.24 0.4
Direct total costs (with acupuncture costs) 42 506.4 (463.7, 548.9) 44 64.4 (20.7, 108.2) 0.13 -441.9
Direct total costs (without acupuncture costs) 42 51.9 (29.1, 74) 44 64.4 (24, 105.6) 0.30 12.5
Indirect costs
loss of income (acupuncture) 42 12.3 (0.1, 24.9)
Productivity loss (acupuncture) 42 39.9 (20.3, 60.2)
loss of income 42 14.0 (-12.5, 39.9) 44 4.0 (-2.3, 10.4) 0.76 -10.0
Productivity loss 42 123.3 (-19.1, 271.1) 44 216.3 (-1.4, 445.1) 0.24 92.9
Indirect total costs (with acupuncture costs) 42 189.7 (245.1, 564.3) 44 220.3 (-6.6, 452.1) 0.90 30.6
Indirect total costs (without 
acupuncture costs)
42 137.4 (-2.1, 275.9) 44 220.3 (-1.7, 449.4) 0.26 82.9
Total costs (with acupuncture costs) 42 696.1 (737.4, 1,085.4) 44 284.7 (32.9, 523.7) 0.26 -411.3
Total costs (without acupuncture costs) 42 189.3 (44.1, 334.4) 44 284.7 (34, 533.9) 0.25 95.4
6-month follow-up
Direct costs
Medication reimbursement 42 15.5 (6.6, 24.3) 44 44.8 (-5.8, 94.6) 0.12 29.3
Medication co-payment 42 20.7 (2.9, 39) 44 12.0 (4.1, 19.7) 0.81 -8.6
Outpatient visits 42 3.2 (2.2, 4.2) 44 3.7 (2.6, 4.9) 0.25 0.5
emergency visits 42 4.2 (1.1, 7.4) 44 6.1 (2.3, 9.6) 0.22 1.8
adverse drug reactions 42 0.1 (-0.1, 0.5) 44 0.3 (-0.3, 1.1) 0.28 0.2
Travel costs 42 7.7 (2.2, 2) 44 4.6 (1.8, 0.0295) 0.86 -3.1
Direct total costs 42 51.7 (28, 76) 44 71.9 (21.8, 124.4) 0.23 20.1
Indirect costs
loss of income 42 3.6 (-3, 10.2) 44 8.3 (0.5, 15.9) 0.18 4.6
Productivity loss 42 10.2 (2.7, 18) 44 51.6 (-10.2, 117.8) 0.085 41.4
Indirect total costs 42 13.9 (6.6, 24.3) 44 59.9 (-5.8, 94.6) 0.075 46.0
Total costs 42 65.7 (2.9, 39) 44 131.9 (4.1, 19.7) 0.071 66.2
Note: Meancontrol - Meanacup, difference between the control group and the group with acupuncture treatment.
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visits, as well as adverse drug reactions, were nearly constant 
in both groups over time.
Patient’s perspective
From patient’s perspective, the essential costs involve the 
costs for acupuncture therapy (€308.5 on average), the travel 
expenses related to treatment (€120.8, on average), and the 
loss of income, which was monitored separately for AG 
and not in the CG, thus increasing the direct costs in the AG 
substantially. Other travel costs and medication co-payment, 
in absolute values, also are slightly higher in the AG, both 
during the acupuncture treatment period and at the 6-month 
follow-up. Loss of income is slightly higher in the AG as 
well but only within the acupuncture treatment period, in the 
6-month follow-up these costs are lower.
societal perspective
From society’s perspective, it is clear that the AG shows 
a lower productivity lost, representing €92.9 during the 
acupuncture treatment period and €41.4 at the 6-month 
follow-up. In this regard, it is a positive phenomenon from 
a societal viewpoint, although the difference in values is 
not significant.
sensitivity analysis
There was no significant difference between AG and CG 
(Table 6). Changes could be observed only in the absolute 
cost values.
Discussion
The present study compares the costs of acupuncture treat-
ment in addition to standard care in patients with migraine 
after a 3-month course and a 6-month follow-up, considering 
the perspectives of a third-party payer, the patient, and the 
society. No significant differences in both direct and indirect 
costs were observed between the groups after acupuncture 
treatment and a 6-month follow-up. Nevertheless, it can be 
stated that AG presented lower costs for productivity losses 
and total indirect costs in comparison with the standard 
pharmacologic therapy at all time periods. As far as total 
direct costs are concerned, during the acupuncture treatment 
period they were higher in the AG, as it was significantly 
influenced by the inclusion of acupuncture costs per session 
and the related travel costs. In addition, it was also a double 
entrance medical examination, both by an internal medicine 
doctor and an acupuncture specialist, which is a specific 
feature of the Faculty Hospital Hradec Kralove. The study, 
nevertheless, points out a potential trend in decreased direct 
costs in connection with reductions in medication intake, 
adverse drug reactions, and ER visits by patients who took 
acupuncture sessions. However, further study in this respect 
is needed.
Similar trends have been described in other studies as 
well; a review by Ambrósio et al10 evaluated seven cost–
utility and one cost-effectiveness analyses of acupuncture 
in the treatment of chronic pain. The conditions treated 
included low back pain, neck pain, dysmenorrhea, migraine 
and headache, and osteoarthritis. Only one cost-effectiveness 
study indicated that there might be both clinical benefits and 
cost savings associated with acupuncture when concerning 
migraine;28 however, another six studies indicated that the 
costs of acupuncture treatment are higher. Notwithstanding, 
a systematic review by Kim et al9 looking at economic 
evaluations, including cost-effectiveness, cost–utility, and 
cost–benefit analyses, alongside randomized controlled 
trials assess the consequences and costs of acupuncture 
for any medical condition. The cost-effectiveness analysis 
proved acupuncture to be beneficial at a relatively low cost 
in six European and Asian studies. However, only one of 
these studies focused on migraine, demonstrating a posi-
tive financial effect on patients in migraine treatment.28 The 
cost estimates in this study included acupuncture, physi-
cian visits, hospital stays, prescription medications, and 
the patients’ incapacity to work. Deng et al11 evaluated 
different types of economic evaluations for acupuncture treat-
ments for migraine in China. The data were obtained from 
Table 6 sensitivity analysis
Acupuncture group N=42 Control group N=44 Bootstrap t, P-value (one tailed) 
Mean 95% CI Mean 95% CI P-value
Direct costs (min price of acupuncture treatment in the czech republic) 398.0 (355.2, 440.6) 64.4 (20.7, 108.2) 0.999
Total cost (min price of acupuncture treatment in the czech republic)a 805.7 (627, 979.8) 284.7 (32.9, 523.7) 0.970
Direct costs (max price of acupuncture treatment in the czech republic) 764.9 (725.8, 806.2) 64.4 (20.7, 108.2) 0.999
Total cost (max price of acupuncture treatment in the czech republic)a 1,172.6 (1,000.9, 1,346.9) 284.7 (32.9, 523.7) 0.999
Notes: acosts are expressed in 2015/2016 eUrO and are varying from €11.0 to €35.0 (cost of acupuncture session) at 0% discount rate.
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a multicenter, randomized controlled trial of acupuncture 
treatment in patients with migraine. Four-hundred eighty 
migraineurs were randomly assigned to three branches of 
treatments with true acupoints. Treatments using specific 
acupoints in Shaoyang meridians are more cost-effective than 
that of non-acupoints, representing a dramatic improvement 
in the quality of life of people with migraine and a significant 
reduction in costs.
The majority of the above-mentioned studies, including 
the present one, have concluded that although acupuncture 
increases health care costs the additional cost can be justi-
fied by the associated short- and long-term improvements 
in clinical outcomes. A study by Wonderling suggested 
the consideration of acupuncture as a viable intervention 
for migraine prophylaxis because it was shown to be a 
cost-effective therapy, relative to a number of interven-
tions recommended by the National Institute for Health 
and Care Excellence, which are provided by the National 
Health Service system.29 Such conclusion was also reached 
by Witt et al in the case of patients with primary headache 
where acupuncture was shown to be a cost-effective treat-
ment according to international cost-effectiveness thresh-
old values.30
The present study was limited by the absence of a double-
blinded method and a small sample size. On the other hand, 
an advantage of the study is the prospective evaluation of 
short- and long-term costs alongside a randomized controlled 
clinical trial. The present study also examined more items 
involved in direct and indirect costs when compared to the 
above-mentioned studies. For instance, in comparison with 
the studies from the review by Ambrósio et al,10 our study 
provides additional data on emergency visits, adverse drug 
reactions, travel costs, productivity loss, and loss of income. 
In addition, both direct and indirect costs were analyzed from 
all three viewpoints, that is, those of the patient, a third-party 
payer, and of society. In conclusion, a 3-month acupuncture 
course resulted in significant short- and long-term clinical 
benefits, while it suggested that acupuncture could be a 
financially attractive treatment option in a longer term, par-
ticularly in the case of indirect costs when compared with 
the absolute values of direct costs. This trend was observed 
also at a 6-month follow-up, although it was not significant. 
In the context of what has been hitherto known from the 
literature about the cost-effectiveness of acupuncture in 
migraine prophylaxis, the integration of acupuncture into 
health care is beneficial for society primarily when concern-
ing lower productivity loss and loss of income, which exceed 
the costs of acupuncture alone. It is, therefore, reasonable 
to recommend acupuncture as an adjuvant treatment to the 
standard pharmacologic therapy in migraine prophylaxis.
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